skip to Main Content

December 16, 2021
2021 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

October 19, 2021
TAG and COVID-19 Prevention Network Fact Sheets
These three fact sheets were developed by TAG in partnership with the COVID-19 Prevention Network (CoVPN) and the Black AIDS Institute (BAI), and they aim to foster community understanding of COVID-19 vaccine research and development, as well as highlight community perspectives on the topic.

October 14, 2021
Time for $5 Coalition Urges Cepheid to Reinstate Plans to Launch GeneXpert Omni
Letter / Comment
The civil society Time for $5 Coalition calls out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urges the company to reinstate plans to launch Omni.

September 15, 2021
Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.

August 31, 2021
Does Delta Mean Change? Community Update on the Delta Variant
Webinar / Presentation
On August 31, 2021, Treatment Action Group (TAG) and Black AIDS Institute (BAI) held a community discussion to get the latest updates on the impact of the Delta variant.

June 4, 2021
2020 Annual Report
As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.

June 3, 2021
TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies
Statement / Press
The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.

May 19, 2021
Breaking Barriers: Surveying Community Perspectives of COVID-19 Vaccine Research
This report aims to raise the profile of discussions that have been taking place regarding community understanding and involvement in COVID-19 vaccine research. It presents the results of an online survey developed by TAG, along with the Black AIDS Institute and the COVID-19 Prevention Trials Network in the fall of 2020…

May 11, 2021
Unique Barriers to COVID-19 Vaccine Access for Black Communities
Webinar / Presentation
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

May 10, 2021
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

May 6, 2021
TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
Statement / Press
Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.

April 29, 2021
Addressing Barriers to Engagement with Faith Communities and COVID-19 Research and Vaccine Uptake
On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community…

April 13, 2021
Civil Society Letter to New WTO Director General: Access to COVID-19 Medical Products
Letter / Comment
TAG joined over 200 other civil society signatories in calling for Dr. Ngozi Okonjo-Iweala, incoming Director General of the World Trade Organization, to move away from interventions to scale up global vaccine supplies for COVID-19 that emphasize biopharmaceutical control of vaccine production and eschew public transparency.

April 6, 2021
Community Update on Current and Future COVID-19 Vaccine Trials
On Tuesday, April 6th Treatment Action Group (TAG) hosted a webinar for community advocates with a status update on current and future COVID-19 vaccine trials and answers to questions related to safety and efficacy data.

April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…

March 5, 2021
How Lessons Learned from the HIV Epidemic Can Inform Efforts to Address the COVID-19 Pandemic Through a Racial Equity Lens
Webinar / Presentation
Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.

February 25, 2021
Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs
Letter / Comment
TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and by lowering cost of its tests for SARS-CoV-2, TB, HIV, HCV, and other diseases…

February 3, 2021
Harnessing the COVID-19 Response Towards Hepatitis C Elimination
Webinar / Presentation
On February 3, 2021, TAG, Médecins du Monde, hepCoalition, and the UNITE network presented a virtual policy dialogue among policymakers, global civil society organizations, and community leaders who share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

February 1, 2021
Harnessing the COVID-19 Response Towards Hepatitis C Elimination
Statement / Press
On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

February 1, 2021
Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination
This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

January 26, 2021
TAG/COVID-19 Prevention Network: HIV, COVID-19 Outcomes and Implications for COVID-19 Vaccines
Webinar / Presentation
Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.

December 16, 2020
TAG and COVID-19 Prevention Network Fall 2020 Webinars
Webinar / Presentation
TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.

December 11, 2020
US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic
Statement / Press
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.

December 2, 2020
Investment in HIV Research Profoundly Benefits the COVID-19 Response
This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.

November 16, 2020
Efficacy News from Second COVID-19 Vaccine Trial Underscores Need for Transparency and Cooperation Between Outgoing and Incoming US Administrations
Statement / Press
AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.

November 12, 2020
COVID-19 and Impacted Communities: A Media Communications Guide
This easy-to-use guide is designed to provide journalists and communication professionals the tools needed to ensure accurate reporting and curb any related stigma associated with the novel coronavirus SARS-COV-2, also known and reported as COVID-19. We invite you to use this to inform your own writing and to share it…

November 9, 2020
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Statement / Press
Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.

November 9, 2020
TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris
Statement / Press
Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.

October 20, 2020
Treatment Action Group Comments for the FDA Advisory Committee Meeting on COVID-19 Vaccines
Letter / Comment
TAG’s comments and recommendations to the FDA Vaccines and Related Biological Products Advisory Committee, encompassing a broad range of community concerns regarding COVID-19 vaccine development and regulatory review.

September 4, 2020
TB Research Investments Provide Returns in Combating Both TB and COVID-19
As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and infrastructure established through years of public and donor investments in…

Back To Top